Laurido-Soto, Osvaldo
Brier, Matthew R.
Simon, Laura E.
McCullough, Austin
Bucelli, Robert C.
Day, Gregory S.
Funding for this research was provided by:
American Academy of Neurology/American Brain Foundation (Clinical Research Training Fellowship)
Article History
Received: 12 November 2018
Revised: 6 December 2018
Accepted: 6 December 2018
First Online: 17 December 2018
Compliance with ethical standards
:
: On behalf of all authors, the corresponding author states that there are no conflicts of interest. Dr. Bucelli receives an annual gift from a patient's family for Parsonage-Turner research; served on an advisory board for MT Pharma; and has equity in Neuroquestions, LLC. Dr. Day has served as a topic editor on dementia for DynaMed Plus (EBSCO Industries, Inc) and as clinical director for the Anti-NMDA Receptor Encephalitis Foundation (uncompensated). Dr. Day receives research/grant support from The American Academy of Neurology/American Brain Foundation, Avid Radiopharmaceuticals, the Foundation for Barnes Jewish Hospital, and the National Institutes of Health (P01AG03991, R56AG057195, U01AG057195) and holds stock in ANI Pharmaceuticals, Inc. Dr. Day has provided record review and expert medical testimony on legal cases pertaining to management of Wernicke encephalopathy. All other authors have no relevant disclosures to report.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.